Zacks Investment Research upgraded shares of Sartorius Ag (NASDAQ:SARTF) from a hold rating to a buy rating in a report published on Thursday, July 27th. They currently have $101.00 price target on the stock.
According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “
Separately, DZ Bank AG reissued a sell rating on shares of Sartorius Ag in a report on Friday, July 21st.
Sartorius Ag (SARTF) remained flat at $89.50 during mid-day trading on Thursday. The company has a market capitalization of $6.12 billion and a P/E ratio of 51.14. Sartorius Ag has a one year low of $75.00 and a one year high of $94.20.
TRADEMARK VIOLATION WARNING: “Sartorius Ag (NASDAQ:SARTF) Upgraded by Zacks Investment Research to Buy” was published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/08/08/sartorius-ag-nasdaqsartf-upgraded-by-zacks-investment-research-to-buy-updated.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sartorius Ag Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius Ag and related companies with MarketBeat.com's FREE daily email newsletter.